Jiaxing Antigon Biotechnology

Antigon Biotechnology is a clinical-stage biopharmaceutical company based in Jiaxing, China, specializing in the development of innovative anti-infective therapies. The company's primary focus is on respiratory viral infections, including influenza, respiratory syncytial virus (RSV), and COVID-19. Its lead candidate, ADC189 (Zunofovir), is a potent small molecule inhibitor of the influenza virus polymerase acidic (PA) protein, designed to provide a more effective treatment option for Influenza A and B. Antigon aims to address significant unmet medical needs in the infectious disease space through its robust R&D pipeline and strategic clinical development. The company has successfully secured significant venture capital funding from prominent investors to advance its programs toward commercialization.